Neurotech | Date: 2013-05-03
The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimers disease, Parkinsons disease and Lou Gehrigs disease.
Neurotech | Date: 2015-06-16
The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.
Neurotech | Date: 2013-05-30
The invention provides cryopreserved encapsulated cell therapy devices that are capable of delivering biologically active molecules as well as methods of using these devices.
Neurotech | Date: 2015-12-30
A thrombus removal means (300) and a thrombus removal device (1) particularly suited to the removal of a thrombus from an intracranial vessel. The thrombus removal means (300) is a mesh structure defining a lumen and is switchable between a contracted configuration and an expanded configuration, the thrombus removal means (300) has a plurality of inwardly arching ribs (321) extending in the lumen, each of the plurality of inwardly arching ribs (321) has a three-dimensional contour and has both ends thereof fixed to the mesh structure. The thrombus removal device (1) includes a guide wire, a pusher shaft (100), an outer sheath (2) and an inner tube (4) movable relative to the outer sheath (2), the guide wire is inserted through the inner tube which is in turn received in the outer sheath and is movable over the guide wire, the thrombus removal device further includes a thrombus removal means.
Neurotech | Date: 2016-05-27
Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
Neurotech | Date: 2013-03-22
The present invention provides a method of determining a treatment program for a subject. The method includes obtaining subject data representing the subjects condition. The subject data is used together with a model of the condition, to determine system values representing the condition. These system values are then used to determining one or more trajectories representing the progression of the condition in accordance with the model. From this, it is possible to determine a treatment program in accordance with the determined trajectories.
Neurotech | Date: 2015-12-22
The invention relates to a device for delivery of pigment epithelium derived factor (PEDF) to the eye utilizing encapsulated PEDF-secreting cells and related methods for the treatment and prevention of ophthalmic diseases and disorders.
Neurotech | Date: 2014-09-10
The invention provides multi-chamber encapsulated cell therapy cartridge devices that are capable of delivering biologically active molecules as well as methods of using these devices.
Neurotech | Date: 2013-04-01
The present disclosure discloses an apparatus to be implanted in eyes, including: a configuration memory used for storing signal parameter configuration; a signal generator connected to the configuration memory and used for generating stimulating signals according to the signal parameter configuration in the configuration memory; electrodes connected to the signal generator and contact with outer surface of eye ball after implanted; a communication assembly connected to the configuration memory and used for receiving the signal parameter configuration, storing the received signal parameter configuration in the configuration memory; and a power supply connected to the configuration memory, signal generator and communication assembly, used for providing power. An update system for the apparatus is also disclosed. By using the above apparatus and update system, when it needs to change waveform parameter of stimulating signals, there is no need to take the apparatus out, reducing harm on human body and improving safety.
Neurotech | Date: 2016-10-26
A luminal stent and a method of fabricating such a luminal stent are disclosed. The luminal stent has a tubular mesh structure formed of metal filaments braided with biodegradable filaments. The luminal stent has the following advantages: 1) it has a thinner wall which facilitates the application of the stent in a narrower vascular lumen with a reduced risk of causing vascular restenosis; 2) it causes a mitigated rejection response of the human body to the presence of the deployed stent as a foreign object and is thus more favorable to tissue endothelialization; and 3) it allows a higher mesh-hole density which makes it possible to change the hemodynamic behavior at a lesion site where the stent is deployed in a more desirable way.